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Abstract
Background:  Inherited differences in the metabolism and disposition of drugs, and genetic
polymorphisms in the targets of drug therapy (e.g., receptors), can greatly influence efficacy and
toxicity of medications. Marked interethnic differences in CYP2C19 (a member of the cytochrome
P-450 enzyme superfamily catalyzing phase I drug metabolism) which affects the metabolism of a
number of clinically important drugs have been documented. The present study evaluated the
activity of CYP2C19 in normal, healthy Gujrati and Marwadi subjects by phenotyping (a western
Indian population).
Methods: All subjects received 20 mg of omeprazole, which was followed by blood collection at
3 hrs to estimate the metabolic ratio of omeprazole to 5-hydroxyomeprazole. The analysis was
done by HPLC.
Results: It was seen that 10.36% of this population were poor metabolizers(PM) whereas 89.63%
were extensive metabolizers(EM).
Conclusion:  A genotyping evaluation would better help in identifying population specific
genotypes and thus help individualize drug therapy.
Background
The differences among individuals in the way they
respond to medications [1] can be attributed to inherited
differences in the metabolism and disposition of drugs,
and genetic polymorphisms in the targets of drug therapy
(e.g., receptors) [2-4] other than the conventional factors
like individual's age and race, organ function, concomi-
tant therapy, drug interactions, and concomitant illnesses
[5]. CYP2C19, a member of the cytochrome P-450
enzyme superfamily(catalyzing phase I drug metabolism)
[6] affects the metabolism of a number of clinically
important drugs, such as proton pump inhibitors (ome-
prazole [7], lanzoprazole, rabeprazole), tricyclic antide-
pressants (imipramine, amitryptiline), phenytoin,
propranolol and benzodiazepines (diazepam) [8].
Marked interethnic differences in the polymorphism fre-
quency [6,9] have led to 21 variant alleles (CYP2C19*2 to
CYP2C19*8) being documented; that predict poor
metabolizers (PMs); of which the most commonly
encountered ones contributing to a PM phenotype were
CYP2C19*2 and CYP2C19*3 genotypes. The prevalence
of PMs has been reported to be 2–5% in Caucasians
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[10,11], 4–8 % in Africans [12] and 11–23 % in Orientals
[11].
Polymorphisms can be determined by phenotyping and
genotyping methodology. The phenotyping method
employs the use of "Probe Drugs". These are drugs which
are characteristically metabolized by a single enzyme sys-
tem and hence can be used to classify individuals as exten-
sive metabolizers (EMs) or poor metabolizers (PMs). The
disadvantages in using older probe drugs like mepheny-
toin has prompted the use of others like omeprazole [13]
and proguanil [14]. The fact that omeprazole is almost
exclusively metabolized by CYP2C19 to 5-hydroxy ome-
prazole and to a lesser extent by CYP3A4 to omeprazole
sulphone makes it a valuable probe drug for establishing
the genotype-phenotype correlation for CYP2C19.
Omeprazole is used in combination regimens for the
treatment of gastric as well as duodenal ulcers, gastro-
esophageal reflux disease and for eradication of Helico-
bacter pylori infection. There exist significant differences in
intragastric pH [15] and differences in cure rates for H.
pylori  infection [16] between extensive metabolizers
(EMs) and poor metabolizers (PMs) who are treated using
omeprazole. Gastric acid suppression and eradication of
H. pylori infection are important determinants in the man-
agement of the pathologies mentioned vide supra. It has
been shown that a higher concentration of omeprazole in
PMs results in greater gastric acid suppression as com-
pared with extensive metabolizers [15]. Whereas the fre-
quency of these polymorphisms in North [17] and South
[18] Indians (who respectively belong to Aryan and Dra-
vidian races) has been documented, the variations in
CYP2C19 activity in Western Indian population has not
been determined so far. The present study thus evaluated
the activity of CYP2C19 in normal, healthy, Gujrati and
Marwadi subjects by phenotyping using omeprazole as
the probe drug.
Methods
Ethics
The study was conducted after approval from the Institu-
tional Review Board, and in accordance with Ethical
Guidelines for Biomedical Research in Human subjects of
ICMR (2000) [19]. Written, informed consent was
obtained from all participating subjects.
Study procedure
The study was conducted in 170 normal healthy (by his-
tory and focused clinical examination) Gujrati and Mar-
wadi subjects residing in the state of Maharashtra,
ensuring that their native places were in the states of
Gujrat and Rajasthan. The sample size was calculated
assuming a 12% prevalence of PMs with 95% CI at 5% sig-
nificance. The prevalence for the sample size calculation
was taken as 12% based on the data of 14% and 12%
prevalence in North [14] and South [15] India respec-
tively. Subjects were admitted to the Clinical Pharmacol-
ogy ward and received Omeprazole 20 mg (Lomac-20®,
batch no: G57688, Cipla Ltd, Mumbai, India) after an
overnight fast. The drug was administered orally under
direct supervision and the blood sample (10 ml of venous
blood collected from an antecubital vein into 1 tube con-
taining 100 µL Heparin) was collected in accordance with
the protocol 3 hours after ingestion of the drug. Alcohol,
caffeine and citrus juices were avoided for at least 48
hours before the intake of omeprazole. The plasma was
separated and stored at -20°C pending further analysis.
Omeprazole and 5-hydroxy omeprazole plasma concen-
trations were determined by reverse phase high perform-
ance liquid chromatography. The analytes were detected
at 302 nm and absorbance was set at 0.005 Aufs. The sen-
sitivity of the method and percentage extraction was 10
ng/ml and 90.0% for both drug and metabolite. The assay
was found to be linear over the concentration range from
0.1 to 10.00 µg/ml with all the concentrations giving pre-
cision and accuracy within 15%. The phenotyping was
done based on minor modifications of the method of
Kobayashi et al. [20]. Statistical analysis was performed
using the Graphpad Instat statistical software (Graph Pad
Software Inc., San Diego, CA, USA). The Kolmogorov-
Smirnov test was used to test normality in the metabolic
ratios.
Results
Of 170 samples 6 samples could not be analyzed for vari-
ous reasons and phenotyping was done for the remaining
164 samples. There were 110 males (67.07%) and 54
females (32.92%), the mean age of the population being
24.79 ± 11.51 (mean ± SD)(95%CI; 26.55, 23.03). Of the
164 subjects, there were 122 Gujratis (77 males and 45
females) and 42 Marwadis (32 males and 10 females). No
subject reported any adverse event to the single dose of the
drug.
The frequency histogram (Figure 1) and the probit plot
(figure 2) of 164 subjects confirmed a bimodal distribu-
tion of subjects with respect to their Metabolic Ratio
(MR). The antimode in the Gujrati and Marwadi (Western
Indian) population was calculated to be 19.54 (log MR =
1.291). Individuals with an MR >19.54 were categorized
as poor metabolizers (PMs), whereas those with
MR<19.54 were categorized as extensive metabolizers
(EMs). The mean MR of the population was 6.52 ± 0.85
(mean ± SEM) (95%CI; 8.198,4.846).
In the study group of 164 volunteers,147 (89.63%) were
EMs with a mean MR of 3.27 ± 0.36 (mean ± SEM) and 17
(10.36%) were PMs with a mean MR of 36.85 ± 3.32
(mean ± SEM). It was further observed that the 55BMC Clinical Pharmacology 2006, 6:8 http://www.biomedcentral.com/1472-6904/6/8
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females, 5(09.09%) were PMs and 50(91.91%) were EMs.
Among the 109 males,12(11.00%) were PMs and
97(89.00%) were EMs. In the individual subgroup of Guj-
ratis, 4(8.88%) of the total 45 females and 10(12.98%) of
the total 77 males were PMs, the % of PMs in the sub-
group as a whole being 11.47%. In the Marwadi sub-
group, 1(10%) of the total 10 females and 2(6.25%) of
the total 32 were PMs, the % of PMs in the subgroup as a
whole being 7.14%.
Discussion and conclusion
Most of the current literature related to pharmacogenetics
of CYP2C19 has studied polymorphisms in Caucasians
[10,11], African-American [11] and Oriental populations
[11], while far less is known about other ethnic groups.
This is the first study from the country to establish the
CYP2C19 phenotype frequencies in the Gujrati and Mar-
wadi (Western Indian) population. Indian population
comprises of more than 1 billion people. The population
is divided into 4 major morphological types – Caucasoid,
Mongoloid, Australoid and Negrito. The states of Mahar-
ashtra (Maharashtrians), Gujrat (Gujratis) and Rajasthan
(Marwadis) belong to the Caucasoid morphological type
[21]. All the subjects of the study are actually migrants to
the city of Mumbai (Bombay). There were 122 Gujratis
and 42 Marwadis. The states of Gujrat and Rajasthan share
a common boundary and have socio cultural, and linguis-
tic similarities and hence the total sample size was taken
as 164 subjects.
It was seen that omeprazole metabolic ratio is a safe and
convenient means for assessing the in-vivo  activity of
CYP2C19. This is in agreement with the use of omepra-
zole as a probe drug in other ethnic populations [22,23].
The prevalence of PMs in Gujratis and Marwadis was
10.36% by phenotyping, which is slightly lower than fre-
quencies of South Indians (14%) [18], North Indians
(12%) [17], Caucasians (3–5%) [10], Africans (8%) [12]
and Orientals (12–23%) [11]. There were differences in
the distribution of PMs in Gujrati men (12.98%PMs) and
women (8.8%PMs);as well as Marwadi men(6.25%PMs)
and women(10%PMs), even though the overall incidence
of PMs in the study group in both sexes was similar. The
number of PMs was too small to do a meaningful statisti-
cal analysis. A total of 7/164 subjects were non vegetari-
ans. Of these, 3 were Marwadis and 4 were Gujratis. None
of the 7 were poor metabolizers and thus cannot explain
Table 1: Data on PMs and EMs in Gujratis and Marwadis
Gujratis n = 122 Marwadis n = 42 Total N = 164
Males n = 109 PM n = 12 10 (12.98%) 2 (06.25%) 12 (11.00%)
EM n = 97 67 (87.02%) 30 (93.75%) 97 (89%)
total 77 32 109
Females n = 55 PM n = 5 4 (08.88%) 1 (10.00%) 5 (09.09%)
EM n = 50 41 (91.12%) 9 (90.00%) 50 (91.91%)
total 45 10 55
Frequency distribution curve of the phenotyping data show- ing demarcation of extensive (EMs) and poor metabolizers  (PMs) based on anti-mode calculations Figure 1
Frequency distribution curve of the phenotyping data show-
ing demarcation of extensive (EMs) and poor metabolizers 
(PMs) based on antimode calculations. Those with antimode 
greater than 19.54 classified as PMs.
Phenotyping data of Gujrati and  Marwadi
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Probit plot obtained by curve fitting the log MR ratio data.
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the PM status. A total of 10 subjects had a very low MR. It
has been reported in literature that super rapid metaboliz-
ers exist and these set of patients are non responders to
proton pump inhibitors. It has been hypothesized to be
caused by variant of the wild type allele. It is possible that
these 10 subjects could belong to this category. [24]
CYP2C19 metabolizes many clinically important drugs,
notably proton-pump inhibitors, proguanil and benzodi-
azepines. The clinical implications of the CYP2C19
metabolism are many and varied, ranging from marked
efficacy in the treatment of Helicobacter pylori infection
with omeprazole in PMs to increased risk of failure of
anti-malarial prophylaxis with proguanil in the same sub-
group. This study was done as a part of a project to deter-
mine the polymorphisms of CYP2C19 by phenotyping as
well as genotyping. The fact that 10.36% of our study pop-
ulation possesses the PM phenotype makes it essential to
evaluate the phenotype-genotypes correlation in this pop-
ulation which can be done after the genotyping data is
available. This is required to circumvent adverse drug reac-
tions associated with increased accumulation of the par-
ent drug and would also serve to decrease cost and
duration of therapy, as a lower dose may suffice in the
individuals who do not metabolize the drug extensively.
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